Accessibility Menu
Clearside Biomedical Stock Quote

Clearside Biomedical (NASDAQ: CLSD)

$3.77
(-3.9%)
-0.15
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.77
Daily Change
(-3.9%) $0.15
Day's Range
$3.68 - $3.97
Previous Close
$3.77
Open
$3.92
Beta
0.97
Volume
21,759
Average Volume
297,469
Market Cap
20.5M
Market Cap / Employee
$3.93M
52wk Range
$3.32 - $18
Revenue
-
Gross Margin
0.83%
Dividend Yield
N/A
EPS
-$5.46
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Clearside Biomedical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CLSD-80.18%-81.57%-28.7%-96%
S&P+15.06%+95.03%+14.29%+220%

Clearside Biomedical Company Info

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.49M446.7%
Gross Profit$0.41M787.0%
Gross Margin82.93%31.8%
Market Cap$62.80M-35.4%
Market Cap / Employee$1.96M0.0%
Employees326.7%
Net Income-$4.50M40.8%
EBITDA-$3.48M53.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$9.38M-48.6%
Accounts Receivable$0.82M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$55.85M18.3%
Short Term Debt$0.38M3.0%

Ratios

Q2 2025YOY Change
Return On Assets-112.50%-21.0%
Return On Invested Capital-129.31%-13.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$4.73M22.5%
Operating Free Cash Flow-$4.73M16.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-2.73-1.87-1.54-1.29-71.07%
Price to Sales12.3243.3018.7614.9515.77%
Price to Tangible Book Value-40.93-30.62-27.14-20.20-69.77%
Enterprise Value to EBITDA-20.70-14.78-21.69-31.32104.86%
Total Debt$49.97M$52.47M$54.06M$56.24M18.16%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.